Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    04112381
Previous Study | Return to List | Next Study

Bilateral Treatment of Medication Refractory Essential Tremor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04112381
Recruitment Status : Recruiting
First Posted : October 2, 2019
Last Update Posted : July 23, 2020
Sponsor:
Information provided by (Responsible Party):
InSightec

Brief Summary:
The purpose of this study is to see if the MR-guided focused ultrasound (MRgFUS) thalamotomy procedure can be performed on both sides of the brain safely and effectively to reduce bilateral tremor.

Condition or disease Intervention/treatment Phase
Essential Tremor Device: Exablate Model 4000 Type 1.0/1.1 Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Trial to Evaluate the Safety and Efficacy of Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor
Estimated Study Start Date : July 2020
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tremor

Arm Intervention/treatment
Experimental: Exablate Secondary Procedure
Thalamotomy
Device: Exablate Model 4000 Type 1.0/1.1
Exablate thalamotomy of non tremor dominant side of the brain




Primary Outcome Measures :
  1. Device and procedure related adverse events [ Time Frame: 3 months ]
    rate of adverse events following the Exablate secondary procedure



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women age 22 years or older
  2. Diagnosis of medication-refractory Essential Tremor
  3. Has previously underwent an Exablate index procedure in a clinical trial or in a commercial setting at least 9 months prior to enrolling in this trial
  4. Able to communicate sensations during the Exablate thalamotomy procedure

Exclusion Criteria:

  1. Has experienced any non-transient neurological event or worsening following the Exablate index procedure
  2. Presence of unknown or MR unsafe devices anywhere in the body
  3. Non-transient hemiparesis as determined by physical examination
  4. Clinically significant abnormal speech function as determined by a speech pathologist
  5. Pregnant or breastfeeding
  6. Unstable cardiac status
  7. Behavior(s) consistent with ethanol or substance abuse
  8. History of bleeding disorder
  9. Has received anticoagulants within one month of Exablate procedure
  10. Cerebrovascular disease
  11. Intracranial tumor
  12. Active or suspected acute or chronic uncontrolled infection
  13. Has previously had deep brain stimulation or a prior stereotactic ablation of the basal ganglia or thalamus
  14. Implanted objects in the skull or the brain
  15. Currently in a clinical trial involving an investigational product or non-approved use of a drug or device or in any other type of medical research
  16. Unable to communicate with the investigator and staff

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04112381


Locations
Layout table for location information
United States, Maryland
University of Maryland Recruiting
Baltimore, Maryland, United States, 21201
Contact: Charlene Aldrich    410-328-5332    cladrich@som.umaryland.edu   
Principal Investigator: Howard Eisenberg, MD         
United States, New York
Weill Cornell Medicine Recruiting
New York, New York, United States, 10065
Contact: Marissa Michael    212-746-7373    mam4001@med.cornell.edu   
Contact: Sophie O'Bryan    212-746-1788    soo4001@med.cornell.edu   
Principal Investigator: Michael Kaplitt, MD         
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Keren Somers    215-829-6720    keren.somers@pennmedicine.upenn.edu   
Contact: Marie Kerr    215-829-6720    kerrm@uphs.upenn.edu   
Principal Investigator: Gordon Baltuch, MD, PhD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Matthew Patterson    434-243-7336    mwp5f@virginia.edu   
Principal Investigator: W. Jeff Elias, MD         
Sponsors and Collaborators
InSightec
Layout table for additonal information
Responsible Party: InSightec
ClinicalTrials.gov Identifier: NCT04112381    
Other Study ID Numbers: ET005
First Posted: October 2, 2019    Key Record Dates
Last Update Posted: July 23, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Tremor
Essential Tremor
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Movement Disorders
Central Nervous System Diseases